Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

2.

Walter

RB

,

Kantarjian

HM

,

Huang

X

, et al.

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

.

J Clin Oncol

.

2010

;

28

(

10

):

1766

-

1771

.

3.

Cheson

BD

,

Cassileth

PA

,

Head

DR

, et al.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

.

J Clin Oncol

.

1990

;

8

:

813

-

819

.

4.

Cheson

BD

,

Bennett

JM

,

Kopecky

KJ

, et al.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

.

J Clin Oncol

.

2003

;

21

:

4642

-

4649

.

5.

Shallis

RM

,

Pollyea

DA

,

Zeidan

AM

.

The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses

.

Blood Rev

.

2021

;

48

:

100806

.

6.

Norsworthy

KJ

,

Gao

X

,

Ko

CW

, et al.

Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses

.

J Clin Oncol

.

2022

;

40

(

8

):

847

-

854

.

7.

Appelbaum

JS

,

Wei

AH

,

Mandrekar

SJ

, et al.

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

.

Leukemia

.

2024

;

38

(

2

):

389

-

392

.

8.

U.S. Food and Drug Administration

.

Guidance for industry. Acute myeloid leukemia: developing drugs and biological products for treatment

. Accessed 4 October 2024. https://www.fda.gov/media/162362/download.

9.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

10.

Estey

EH

,

Shen

Y

,

Thall

PF

.

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

.

Blood

.

2000

;

95

(

1

):

72

-

77

.

11.

Ciftciler

R

,

Demiroglu

H

,

Haznedaroglu

IC

, et al.

Impact of time between induction chemotherapy and complete remission on survival outcomes in patients with acute myeloid leukemia

.

Clin Lymphoma Myeloma Leuk

.

2019

;

19

(

11

):

729

-

734

.